Look for:

Our offer for

SEAGEN INC.


ISIN:
US81181C1045
WKN:
81181C104

2023/09/29 22:00:00
Price
212.15 USD
Difference -0.04% (-0.09)

General attributes

ISINUS81181C1045
SymbolSGEN
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)37,696 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)212.15 USD (100)
Ask (Ask size)220.00 USD (100)
Open212.12 USD
High213.50 USD
Low212.12 USD
Close (prev. day)212.24 USD
VWAP212.509603 USD
Volume (pcs)1,286,777
Trading volume273,475,928.33
Number of trades16,155
Last size179,352

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Company report: SEAGEN INC.PDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2023/09/29 22:00:00
Price
212.15 USD
Difference -0.04% (-0.09)

General attributes

ISINUS81181C1045
SymbolSGEN
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)37,696 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)212.15 USD (100)
Ask (Ask size)220.00 USD (100)
Open212.12 USD
High213.50 USD
Low212.12 USD
Close (prev. day)212.24 USD
VWAP212.509603 USD
Volume (pcs)1,286,777
Trading volume273,475,928.33
Number of trades16,155
Last size179,352

Performance and Risk

6m1Y3Y
Perf (%)+4.91%+56.34%+11.10%
Perf (abs.)+9.92+76.45+21.19
Beta0.200.230.63
Volatility15.0032.2038.00
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)213.72 USD (2,164,202)
Ø price 30 days | Ø volume 30 days (pcs.)205.92 USD (1,584,399)
Ø price 100 days | Ø volume 100 days (pcs.)198.31 USD (1,324,922)
Ø price 250 days | Ø volume 250 days (pcs.)171.91 USD (1,260,675)
YTD High | date217.08 USD (2023/09/26)
YTD Low | date126.47 USD (2023/01/10)
52 Weeks High | date217.08 USD (2023/09/26)
52 Weeks Low | date116.08 USD (2022/12/06)

All listings for SEAGEN INC.

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Tradegate2023/09/2922:26200.80 EUR0.014
Stuttgart2023/09/2913:14200.20 EUR0.006
Nasdaq2023/09/2922:00212.15 USD273.4816,155
Munich2023/09/2908:00200.00 EUR0.001
London Stock Exchange2023/09/2213:34214.00 USD0.971
Frankfurt2023/09/2921:43200.60 EUR0.002
Berlin2023/09/2908:08200.00 EUR0.001
BX Swiss---0.00-

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=137070&ID_TYPE_IMAGE_LOGO=2

Contact Details

SEAGEN INC.
- -
21823 30th Drive South East - 98021 Bothell
Telefon: +1-425-527-4000
Fax: +
E-mail: contact@seagen.com

PDF Downloads

Company report: SEAGEN INC.PDF Download

Company Profile

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Members of Management Board

Felix BakerChairman of Board of Directors
Alpna SethMember of Board of Directors
Nancy SimonianMember of Board of Directors
Sandra SwainMember of Board of Directors
Ted LoveMember of Board of Directors
Daniel WelchMember of Board of Directors
David GryskaMember of Board of Directors
John OrwinMember of Board of Directors
Clay B. SiegallChairman of Managing Board
Vaughn B. HimesMember of Executive Committee
Charles RompMember of Executive Committee
Christopher PawlowiczMember of Executive Committee
Jean I. LiuMember of Executive Committee
Natasha HerndayMember of Executive Committee
Roger D. Dansey, M.D.Member of Executive Committee
Todd E. SimpsonMember of Executive Committee
Tuomo PätsiMember of Executive Committee






Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer